𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of oral miltefosine in patients with squamous cell head and neck cancer

✍ Scribed by Verweij, J.; Planting, A.S.Th.; Stoter, G.; Gandia, D.; Armand, J.P.

Book ID
122378107
Publisher
Elsevier Science
Year
1993
Tongue
English
Weight
204 KB
Volume
29
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase II study of piritrexim in patien
A phase II study of piritrexim in patients with advanced squamous head and neck cancer
✍ Wu-Ching Uen; Andrew T. Huang; Robert Mennel; Stephen E. Jones; Monica B. Spauld πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 347 KB πŸ‘ 3 views

Piritrexim (PTX) is a newly developed lipid-soluble folate antagonist that crosses the cell membrane by a simple, rapid, carrier-independent diffusion process. A Phase II study was conducted to evaluate the activity of PTX in 34 patients with previously chemotherapy-naive squamous cell cancer of the

A phase II study of mitoxantrone in adva
A phase II study of mitoxantrone in advanced squamous cell cancer of the head and neck
✍ H. Wheeler; R. L. Woods; J. Page; J. Levi πŸ“‚ Article πŸ“… 1990 πŸ› Springer US 🌐 English βš– 186 KB

Twenty patients with advanced squamous cell carcinomas (SCC) of the head and neck were entered into a phase II study of mitoxantrone at a dosage of either 12 mg/m2 or 14 mg/m2 given at 3 weekly intervals. None of the patients had received prior chemotherapy. One patient had a partial remission. Two